EU and US could reach trade deal this weekend - Reuters
Investing.com - Mizuho (NYSE:MFG) raised its price target on Boston Scientific (NYSE:BSX) to $140.00 from $130.00 on Thursday, while maintaining an Outperform rating on the medical device maker’s stock. The company, with a market capitalization of $159 billion, has demonstrated strong financial health according to InvestingPro analysis, though current trading levels suggest the stock is trading above its Fair Value.
The firm cited strong performance in Boston Scientific’s FARAPULSE and WATCHMAN product lines, which are expected to offset an 800 basis point growth impact from the global recall of the company’s ACURATE transcatheter aortic valve replacement (TAVR) system in the second half of the year. The company’s stock has shown remarkable momentum, gaining over 20% year-to-date and currently trading near its 52-week high of $108.94.
Mizuho noted that Boston Scientific’s electrophysiology (EP) segment grew 94% in the latest quarter, exceeding market expectations of 90%, driven by U.S. FARAPULSE volumes in de novo paroxysmal and persistent atrial fibrillation cases, along with share gains for the Opal EP mapping system. This impressive segment performance contributes to the company’s overall revenue growth of 19.4% in the last twelve months. Get deeper insights into Boston Scientific’s growth metrics and 15+ additional ProTips with an InvestingPro subscription.
The WATCHMAN device showed accelerated growth of 28%, up from 25% in the first quarter, which Mizuho attributed to concomitant pulsed field ablation cases and recent label expansion as a first-line therapy for post-ablation patients.
Boston Scientific remains on track to receive clearances for FARAPULSE in China and Japan before year-end, while the company has no plans to re-engineer the ACURATE valve, effectively putting it "at square one in the TAVR space," according to Mizuho’s analysis.
In other recent news, Boston Scientific reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share of $0.75, compared to a forecast of $0.73. The company also exceeded revenue expectations, reporting $5.06 billion against the anticipated $4.89 billion. This performance highlights the company’s robust financial health and operational success. UBS raised its price target for Boston Scientific to $135, maintaining a Buy rating, citing strong product cycles and sales performance. Wells Fargo (NYSE:WFC) also increased its price target to $124, noting significant momentum in the company’s Pulse Field Ablation technology and increased adoption of the Watchman device. Additionally, BofA Securities adjusted its price target to $120, following an analysis of Boston Scientific’s second-quarter financial results. These developments indicate strong market confidence in the company’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.